News of Note—Gritstone’s EVP, Trump’s opioid vaccine plan and more

non
In this week's news of note, Gritstone Oncology hired an industry veteran as its technical operations head. (Pixabay)

Here's some other vaccine news of note for the week.

> Cancer vaccine startup Gritstone Oncology hired Jayant Aphale, Ph.D., as EVP of technical operations. He previously served senior roles at Sarepta, GlaxoSmithKline Vaccines, Acambis and Wyeth Vaccines. Release

> President Donald Trump unveiled a new plan to combat the opioid crisis, including support for research into developing a vaccine for opioid addiction. CNBC article

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

> The Philippine government will seek congressional permission to use refunds for unused Dengvaxia shots from Sanofi to support related medical needs of those already inoculated. ABS-CBN article

> TapImmune’s shares rose 17% premarket Thursday after the company said its TPIV200 T-cell vaccine did well in a phase 1 study in patients with ovarian and breast cancer. MarketWatch article

Suggested Articles

Merck just last month won the world's first licensure for an Ebola vaccine. Now, an international group authorized funding to establish a stockpile.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.